Tumor infiltrating CD8+ and CD4+ T cells remain an important predictor of patient outcomes and responsiveness to anti-PD-1 therapy, with recent discoveries highlighting a role for TCF7+CD8+ T cells in predicting responsiveness [36–39]. This evidence concerns the gene CD4 and neoplasm.